Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab versus Rebif in relapsing multiple sclerosis (Study Two)
ISRCTN70702834Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of alemtuzumab in multiple sclerosis (MS) (3 arms), sponsored by Sanofi. Primary endpoints: Time to sustained accumulation of disability and Relapse rate. Started Oct 2007; status: completed.
02
Drugs
alemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ISRCTN70702834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN70702834.